HIV drug resistance testing has become an integral part of HIV clinical care. Commercially available genotypic assays identify drug resistance mutations through population sequencing of regions of the HIV protease and reverse transcriptase genes. However, these assays are insensitive to drug resistance variants when present at levels comprising less than 10 to 20 percent of the virus population.
By contrast, ultradeep sequencing allows the identification of HIV nucleotide variants and variant haplotype signatures present at <1% in patient samples. Tracking of viral haplotypes, which requires long-sequence read lengths, is particularly useful in determining whether sequentially expressed dual infections are the consequence of viral evolution, co-infection, or superinfection.
This webinar presents insight into the characterization of HIV by next-generation sequencing, including data obtained from a comparison of HIV drug-resistance variant detection in a 465-base region of HIV reverse transcriptase by the Illumina MiSeq and Roche 454 GS FLX+ platforms.